3762
B. A. Aleiwi, M. Kurosu / Tetrahedron Letters 53 (2012) 3758–3762
1997, 62, 1368–1375; (b) Fraser, A. S.; Kawasaki, A. M.; Jung, M. E.; Muthiah, M.
References and notes
Tetrahedron Lett. 2000, 41, 1523–1526; (c) Prakash, T. P.; Kawasaki, A. M.;
Lesnik, E. A.; Owens, S. R.; Manoharan, M. Org. Lett. 2003, 5, 403–406; (d)
Hirano, S.; Ichikawa, S.; Matsuda, A. Angew. Chem., Int. Ed. 2005, 44, 1854–1856;
(e) Hirano, S.; Ichikawa, S.; Matsuda, A. J. Org. Chem. 2007, 72, 9936–9946; (f)
Kodama, T.; Matsuo, C.; Ori, H.; Miyoshi, T.; Obika, S.; Miyashita, K.; Imanishi, T.
Tetrahedron 2009, 41, 2116–2123; (g) Tanino, T.; Ichikawa, S.; Shiro, M.;
Matsuda, A. J. Org. Chem. 2010, 75, 1366–1377; (h) Jensen, T. B.; Pasternak, A.;
Madsen, A. S.; Petersen, M.; Wengel, J. Chem. Bio. Chem. 2011, 12, 1904–1911.
5. (a) Connor, D. S.; Klein, G. W.; Taylor, G. N.; Boeckman, R. K.; Medwid, J. B. Org.
Syn. 1972, 52, C10–19; (b) Hanessian, S.; Kloss, J.; Sugawara, T. J. Am. Chem. Soc.
1986, 108, 2758–2759; (c) Goff, D. A.; Harris, R. N.; Bottaro, J. C.; Bedford, C. D. J.
Org. Chem. 1986, 51, 4711–4714; (d) Kunz, H.; Waldman, H. Protecting Groups
In Comprehensive Organic Synthesis; Trost, B. M., Fleming, I., Eds.; Pergamon
Press: Oxford, United Kingdom, 1991; Vol. 6, pp 631–701. Chapter 3.1; (e)
Prakash, T. P.; Manoharan, M.; Kawasaki, A. M.; Fraser, A. S.; Lesnik, E. A.; Sioufi,
N.; Leeds, J. M.; Teplova, M.; Egli, M. Biochemistry 2002, 41, 11642–11648.
6. Spork, A. P.; Wiegmann, D.; Granitzka, M.; Stalke, D.; Ducho, C. J. Org. Chem.
2011, 76, 10083–10098.
7. We screened a wide range of primary and secondary amines, and pyridines to
suppress the over-reductions of the uracil double bond during hydrogenolytic
deprotections of the BOM group of the uridine derivatives. Addition of amines
to Pd-mediated hydrogenation conditions did not provide the desired BOM-
deprotected products in satisfactory yield.
8. (a) Daubert, B. F.; King, C. G. J. Am. Chem. Soc. 1939, 61, 3328–3330; (b) Bajwa, J.
S. Tetrahedron Lett. 1992, 33, 2299–2302; (c) Shue, Y.-K.; Carrera, G. M.; Tufano,
M. D.; Nadzan, A. M. J. Org. Chem. 1991, 56, 2107–2111.
1. (a) Yamaguchi, H.; Sato, S.; Yoshida, S.; Takeda, K.; Itoh, M.; Seto, H.; Otake, N. J.
Antibiot. 1986, 39, 1047–1053; (b) McDonald, L. A.; Barbieri, L. R.; Carter, G. T.;
Lenoy, E.; Lotvin, J.; Peterson, P. J.; Siegel, M. M.; Singh, G.; Williamson, R. T. J.
Am. Chem. Soc. 2002, 124, 10260–10261; (c) Muramatsu, Y. M.; Inukai, M. J.
Antibiot. 2003, 56, 253–258; (d) Igrashi, M.; Nakagawa, M.; Doi, S.; Hattori, N.;
Naganwa, H.; Hamada, M. J. Antibiot. 2003, 56, 580–583; (e) Kimura, K.; Bugg, T.
D. H. Nat. Prod. Rep. 2003, 20, 252–273; (f) Bryskier, A.; Dini, A. C. Agents:
Antibacter. Antifung. 2005, 377–398; (g) Timothy, D. H.; Lloyd, A. J.; Roper, D. I.
Infect. Disorders: Drug Targets 2006, 6, 85–106; (h) Murakami, R.; Fujita, Y.;
Kizuka, M.; Kagawa, T.; Muramatsu, Y.; Miyakoshi, S.; Takatsu, T.; Inukai, M. J.
Antibiot. 2007, 60, 690–695; (i) Winn, M.; Goss, R. J. M.; Kimura, K.; Bugg, T. D.
H. Nat. Prod. Rep. 2010, 27, 279–304; (j) Guillemette, C.; Levesque, E.; Harvey,
M.; Bellemare, J.; Menard, V. Drug Metabo. Rev. 2010, 42, 24–44; (k) Yamamoto,
T.; Koyama, H.; Kurajoh, M.; Shoji, T.; Tsutsumi, Z.; Moriwaki, Y. Clin. Chim. Acta
2011, 412, 1712–1724.
2. (a) Fang, X.; Gibbs, B. S.; Coward, J. K. Bioorg. Med. Chem. Lett. 1995, 5, 2701–
2706; (b) Boojamra, C. G.; Lemoine, R. C.; Blais, J.; Vernier, N. G.; Stein, K. A.;
Magon, A.; Chamberland, S.; Hecker, S. J.; Lee, V. J. Bioorg. Med. Chem. Lett. 2003,
13, 3305–3309; (c) Hotoda, H.; Furukawa, M.; Daigo, M.; Murayama, K.;
Kaneko, M.; Muramatsu, Y.; Ishii, M. M.; Miyakoshi, S.; Takatsu, T.; Inukai, M.;
Kakuta, M.; Abe, T.; Harasaki, T.; Fukuoka, T.; Utsuic, Y.; Ohyac, S. Bioorg. Med.
Chem. Lett. 2003, 13, 2829–2832; (d) Yamashita, A.; Norton, E.; Petersen, P. J.;
Rasmussen, B. A.; Singh, G.; Yang, Y.; Mansour, T. S.; Ho, D. M. Bioorg. Med.
Chem. Lett. 2003, 13, 3345–3350; (e) Koga, T.; Fukuoka, T.; Harasaki, T.; Inoue,
H.; Hotoda, H.; Kakuta, M.; Muramatsu, Y.; Yamamura, N.; Hoshi, M.; Hirota, T.
J. Antimicrob. Chemother. 2004, 54, 755–760; (f) Dini, Christophe. Curr. Top. Med.
Chem. 2005, 5, 1221–1236; (g) Reddy, V. M.; Einck, L.; Nacy, C. A. Antimicrob.
Agents Chemother. 2008, 52, 719–721; (h) Ichikawa, S. Chem. Pharm. Bull. 2008,
56, 1059–1072; (i) Dini, C.; Drochon, N.; Feteanu, S.; Guillot, J. C.; Peixoto, C.;
Aszodi, J. Bioorg. Med. Chem. Lett. 2001, 11, 529–531.
9. General procedure for BOM deprotections: To a stirred solution of the BOM
protected uridine derivative (1 equiv) in iPrOH:H2O (10:1) and HCO2H (0.5%)
was added 10% Pd–C (10%) under N2. H2 gas was introduced to the reaction
mixture using a double-folded balloon. Upon completion, the reaction mixture
was filtered through a Celite pad and washed with EtOAc (or MeOH). All
volatiles were evaporated in vacuo. When the HCO2H-amine salt was
generated, the crude mixture was dissolved in CHCl3 and washed with aq.
NaHCO3. The combined organic extracts were dried over Na2SO4 and
evaporated in vacuo. Purification by silica gel chromatography afforded the
desired compound (yields are given in Tables 1 and 2).
3. (a) Kurosu, M.; Li, K.; Crick, D. C. Org. Lett. 2009, 11, 2393–2397; (b) Kurosu, M.;
Li, K. J. Org. Chem. 2008, 73, 9767–9771; (c) Kurosu, M.; Biswas, K.; Crick, D. C.
Org. Lett. 2007, 9, 1141–1145; (d) Kurosu, M.; Narayanasamy, P.; Crick, D. C.
Heterocycles 2007, 72, 339–352; (e) Kurosu, M.; Mahapatra, S.; Narayanasamy,
P.; Crick, D. C. Tetrahedron Lett. 2007, 48, 799–803; (f) Wang, Y.; Kurosu, M.
Tetrahedron 2012, 68, 4797–4804.
10. Reported amine additives for controlled-hydrogenation conditions with Pd
species have relatively high boiling point.
4. Synthesis of uridine-containing natural products using the BOM-protecting
group, see: (a) Ichikawa, S.; Shuto, S.; Minakawa, N.; Matsuda, A. J. Org. Chem.